, suggesting markets were set for another seesaw day driven by uncertainty regarding the potential impact of the Omicron Covid-19 variant. :
Shares of Vir Biotechnology jumped almost 10% premarket after a Covid-19 antibody treatment developed by it and GlaxoSmithKline was effective against the Omicron variant in early laboratory studies, the companies said, setting it apart from similar therapies that appear to work less well against the highly mutated strain.
, including its latest one, and that management has concluded there was a material weakness in its internal control.that the company told suppliers that demand for the iPhone 13 lineup has weakened.
do ESG revolution! do ESG blockchain revolution!
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: Reuters - 🏆 2. / 97 더 많은 것을 읽으십시오 »
출처: Forbes - 🏆 394. / 53 더 많은 것을 읽으십시오 »
출처: trtworld - 🏆 101. / 63 더 많은 것을 읽으십시오 »